Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (DAYVIGO® CIV) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to June 8, 2022, in Charlotte, NC.
Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).
“DAYVIGO continues to serve as an important asset to Eisai’s neurology portfolio and we look forward to presenting the findings from several analyses at this year’s SLEEP Meeting,” said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. “Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability, 1, 2 and causes distress or impairs functioning in social and occupational settings.3 Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs.”
References
1. Ferrie JE, et al. Sleep epidemiology – a rapidly growing field. Int J Epidemiol. 2011;40(6):1431–1437.
2. Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7–S10.
3. National Institute of Public Health. Sleep disorders practice guidelines – for the proper usage of sleeping medications and the withdrawal: insomnia medical manual aiming for breaking through (available in Japanese only).
Source: Eisai
Pingback: E2086 Showed Potential to Improve Narcolepsy Treatment - SleepWorld Magazine